Novel coronavirus of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new strain that has resulted in the 2019 coronavirus disease pandemic (COVID-19). COVID-19 was identified for the first time in the city of Wuhan, China. Other coronavirus infections include the common cold (HCoV229E, NL63, OC43, and HKU1), Middle East Respiratory Syndrome (MERS-CoV), and SARS-CoV. The SARS-CoV and the MERS-CoV epidemics resulted in 10,000 cumulative cases over two decades. The mortality rate was 10% for SARS-CoV, and 37% for RR MERS-CoV. COVID-19 belongs to the same \( \beta \)-coronavirus subgroup, and it has a genome similarity of about 80% and 50% with SARS-CoV and MERS-CoV, respectively.

The symptoms of COVID-19 disease are mostly mild. They include upper respiratory tract infection symptoms, such as fever, fatigue, tiredness, and dry cough. Some patients may develop a runny nose with congestion, sore throat, or diarrhea. Others get the infection without developing any symptoms. As a result, most (80%) people recover without any treatment. Older people, and those with chronic medical problems such as diabetes, hypertension, chronic lung diseases, and cardiovascular disease, are more likely to develop severe illness.
The severe form can be critical and result in rapid deterioration of the medical condition. Therefore, identifying factors that could predict the negative outcome of COVID-19 disease is essential to improve our response to the COVID-19 pandemic to improve patients’ outcomes.

Multigorgan failure is considered one of the significant causes of death in patients with SARS disease in 2003 and the current COVID-19 pandemic. Indeed, multigorgan dysfunction, including liver and renal injuries, has been reported in around one-third of SARS and COVID-19 patients. This study’s objective was to investigate the estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease (MDRD) equation among COVID-19 patients and to examine its correlation with different demographic, clinical, and laboratory characteristics as well as outcomes of COVID-19 disease.

**METHODS**

This study evaluated the renal parameters of COVID-19 patients admitted to Al Kuwait Hospital, the only federal hospital in Dubai, UAE, from March to April 2020. During the same period, a control group without COVID-19 infection were recruited from the outpatient’s department.

The study was approved by the Ministry of Health and Prevention (MOHAP) Research Ethics Committee (MOHAP/DXB-REC/MMM/NO.44/2020). The demographic, clinical, and laboratory characteristics of patients were collected prospectively. MOHAP has an electronic file system that is connected to the rest of the federal hospitals across the UAE. Each patient has a single medical identifier number with a single health file. The medical identifier number is connected to the national identifier number, facilitating tracing all the needed medical information.

The characteristics of patients were collected prospectively from the electronic file system. The collected data included demographic characteristics like age and gender, medical comorbidities, COVID-19 symptoms at presentation, and their severity, progression, and outcomes. We also collected data on inflammatory markers, including C-reactive protein (CRP), ferritin, procalcitonin, lactate dehydrogenase (LDH), 5-coagulation profile, D-dimer, and international normalized ratio (INR); laboratory parameters including detailed blood rheology, liver function tests including alanine transaminase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), serum bilirubin, and albumin; electrolytes that included sodium (Na) and potassium (K); and renal function parameters, urea, and serum creatinine (SCr). Past medical history of hypertension was defined as blood pressure > 140/90 or the use of antihypertensive medications or dietary advice, and diabetes mellitus (DM) was defined as a plasma blood glucose of > 6.9 mmol/L or the patient was taking anti-diabetic medications or/and on lifestyle modification.

The Ministry of Health laboratory system uses the MDRD formula, six variable equation, 186 × (SCr mg/dL)-1.154 × (age)-0.203 × 0.742 [if female] × 1.212 [if black], to calculate the eGFR for all participants.

COVID-19 severity had been categorized as 1) mild to moderate COVID-19 if there was no pneumonia, if there was mild pneumonia based on chest radiography, or chest computed tomography (CT) findings; 2) severe COVID-19 disease, if there was dyspnea, respiratory rate ≥ 30/minute, blood oxygen saturation ≤ 93%, PaO2/FiO2 ratio < 300, and/or lung infiltrates > 50% within 24–48 hours; and 3) critical COVID-19 infection, if there was respiratory failure, septic shock, and/or multiple organ dysfunction/failure.

For the continuous variables, the data were tabulated and presented as mean and standard deviation. For categorical variables, frequencies and percentages were used, while Pearson’s chi-squared test was used for comparisons. Student’s t-test was used to compare COVID-19 and non-COVID-19 patients in Table 1 while differences between the different eGFR groups were analyzed using analysis of variance (ANOVA) test [Tables 2 and 3]. Correlations between the renal parameters (eGFR, serum urea, and creatinine) and the various laboratory parameters were analyzed using Pearson’s...
Table 1: Demographic and laboratory features of COVID-19 patients compared with the control group.

| Characteristics          | COVID-19 infection | Control (n = 153) | p-value |
|--------------------------|--------------------|-------------------|---------|
|                          | Patients (n = 250) |                   |         |
| Age, mean ± SD, years   | 46.0 ± 14.8        | 49.1 ± 12.5       | 0.017   |
| Male gender, n (%)      | 191 (76.4)         | 29 (19.0)         | < 0.001 |
| eGFR, mean ± SD, ml/min/1.73 m² | 91.0 ± 30.1       | 96.7 ± 20.9       | < 0.001 |
| Level of renal impairment* |                   |                   |         |
| Normal                   | 135 (54.7%)        | 106 (69.3%)       |         |
| Mild                     | 78 (31.6%)         | 37 (24.2%)        | 0.050   |
| Moderate-severe          | 34 (13.8%)         | 10 (6.5%)         |         |
| Urea, mean ± SD, mmol/L | 6.2 ± 7.7          | 4.3 ± 1.4         | < 0.001 |
| Creatinine, mean ± SD, μmol/L | 107.2 ± 159.7     | 60.2 ± 17.1       | 0.003   |
| Sodium, mean ± SD, mmol/L | 136.8 ± 4.5        | 138.5 ± 2.2       | < 0.001 |
| Potassium, mean ± SD, mmol/L | 4.0 ± 0.6         | 4.1 ± 0.3         | 0.500   |
| Platelet, mean ± SD, ×10^9/L | 243.1 ± 88        | 278.1 ± 84.4      | 0.339   |
| Hemoglobin, mean ± SD, g/dL | 13.4 ± 1.9        | 12.5 ± 1.6        | 0.004   |
| White cell count, mean ± SD, ×10^9/L | 8.9 ± 10.7      | 6.8 ± 2.1         | 0.007   |

SD: standard deviation; eGFR: estimated glomerular filtration rate.
*Three cases (out of the 250) had missing serum creatinine levels and were not included in the eGFR calculations.

Table 2: The association between eGFR* levels and the demographic, clinical features, and risk factors of the COVID-19 patients.

| Characteristic, n (%) unless specified otherwise | Normal (135, 54.7) | Mild (78, 31.6) | Moderate (23, 9.3) | Severe (11, 4.5) | p-value |
|--------------------------------------------------|--------------------|----------------|-------------------|-----------------|---------|
| Demographic                                      |                    |                |                   |                 |         |
| Age, mean ± SD, years                            | 40.2 ± 12.6        | 50.3 ± 14.0    | 58.3 ± 14.2       | 62.5 ± 8.9      | < 0.001 |
| Male, gender                                     | 96 (71.1)          | 60 (76.9)      | 22 (95.7)         | 11 (100)        | 0.016   |
| Time from symptom onset to admission, mean ± SD, days | 5.7 ± 3.0         | 5.7 ± 2.9      | 5.7 ± 3.4         | 5.3 ± 3.3       | 0.981   |
| Clinical presentation                            |                    |                |                   |                 |         |
| Fever                                            | 79 (58.5)          | 50 (64.1)      | 16 (69.6)         | 7 (63.6)        | 0.710   |
| Cough                                            | 62 (45.9)          | 47 (60.3)      | 12 (52.2)         | 8 (72.7)        | 0.260   |
| Shortness of breath                              | 47 (34.8)          | 27 (34.6)      | 10 (43.5)         | 5 (45.5)        | 0.800   |
| Comorbidities                                    | 54 (40.0)          | 39 (50.0)      | 21 (91.3)         | 10 (90.9)       | < 0.001 |
| Risk factors                                     |                    |                |                   |                 |         |
| Cardiovascular disease                           | 3 (2.2)            | 3 (3.8)        | 1 (4.3)           | 1 (9.1)         | 0.600   |
| Diabetes mellitus                                | 29 (21.5)          | 22 (28.2)      | 18 (78.3)         | 8 (72.7)        | < 0.001 |
| Hypertension                                     | 34 (25.2)          | 21 (26.9)      | 13 (56.5)         | 8 (72.7)        | 0.003   |
| Chronic lung diseases                            | 4 (3.0)            | 5 (6.4)        | 0 (0.0)           | 0 (0.0)         | 0.367   |
| Chronic kidney disease                           | 0 (0.0)            | 0 (0.0)        | 2 (8.7)           | 2 (18.2)        | 0.001   |
| Disease severity                                 |                    |                |                   |                 |         |
| Mild-moderate                                     | 78 (57.8)          | 38 (48.7)      | 7 (30.4)          | 0 (0.0)         |         |
| Severe                                           | 35 (25.9)          | 22 (28.2)      | 4 (17.4)          | 4 (36.4)        | < 0.001 |
| Critical                                         | 22 (16.3)          | 18 (23.1)      | 12 (52.2)         | 7 (63.6)        |         |
| ICU admission                                     | 22 (16.3)          | 18 (23.1)      | 12 (52.2)         | 8 (72.7)        | < 0.001 |

SD: standard deviation; eGFR: estimated glomerular filtration rate; ICU: intensive care unit.
*Three cases (out of the 250) had missing serum creatinine levels and they were not included in the eGFR calculations.
correlation coefficient (r) [Table 4]. A p-value of < 0.050 was used as a cut-off value to differentiate between significant or non-significant differences. SPSS 26.0 (IBM Corporation, Armonk, NY) software was used for statistical analysis.

**RESULTS**

During the study period, 403 patients were enrolled, 62.0% (n = 250) were positive for COVID-19 while 38.0% (n = 153) did not have infection. The overall mean age of the cohort was 47.2 ± 14.0 years and 54.6% (n = 220) were males. Table 1 shows the demographic and laboratory features of the study participants. Compared to the control group, COVID-19 patients were younger (46.0 vs. 49.1 years; p = 0.017), associated with significantly higher levels of blood urea (6.2 vs. 4.3 mmol/L; p < 0.001), Scr (107.2 vs. 60.2 µmol/L; p = 0.003) and white cell count (WCC) (8.9 vs. 6.8 × 10⁹/L; p = 0.007). The eGFR was lower in COVID-19 patients than in controls (91.0 vs. 96.7 mL/min/1.73 m²; p < 0.001). Further classification of eGFR of the study sample revealed that COVID-19 patients were marginally associated with more moderate to severe renal impairment than the control group (13.8% vs. 6.5%; p = 0.050).

Table 2 shows the association between eGFR levels and the various demographic and clinical features of the 250 COVID-19 patients. When compared to those with normal eGFR, those with severe renal impairment were older (62.5 vs. 40.2
years; \(p < 0.001\)), more likely to be male (100% vs. 71.1%; \(p = 0.016\)), and have comorbidities (90.9% vs. 40.0%; \(p < 0.001\)) including DM (72.7% vs. 21.5%; \(p < 0.001\)) and hypertension (72.7% vs. 25.2%; \(p = 0.003\)). They were also more likely to be associated with those that had severe (36.4% vs. 25.9%; \(p < 0.001\)) and critical (63.6% vs. 16.3%; \(p < 0.001\)) COVID-19 infection as well as intensive care unit (ICU) admission (72.7% vs. 16.3%; \(p < 0.001\)).

The associations between eGFR levels and radiological as well as laboratory parameters in 250 COVID-19 cases is outlined in Table 3. Compared to those with normal eGFR, those with severe renal impairment were more likely to be associated with bilateral air space consolidation (100% vs. 40.7%; \(p < 0.001\)), higher neutrophil count (12.5 vs. 5.3 \(\times 10^9\)/L; \(p = 0.009\)), ferritin levels (2618.0 vs. 893.0 ng/mL; \(p = 0.002\)), CRP (181.7 vs. 47.4 mg/L; \(p < 0.001\)), urea (27.8 vs. 4.1 mmol/L; \(p < 0.001\)), K (4.6 vs. 4.0 mmol/L; \(p < 0.001\)), INR (1.2 vs. 1.01; \(p = 0.001\)), LDH (551.5 vs. 313.3 U/L; \(p < 0.001\)), ALP (95.6 vs. 77.9 IU/L; \(p = 0.039\)) and procalcitonin (4.9 vs. 0.4 \(\mu\)g/L; \(p < 0.001\)). However, those with severe renal impairment were associated with lower levels of hemoglobin (11.1 vs. 13.5 g/dL; \(p < 0.001\)), lymphocyte count (0.8 vs. 3.0 \(\times 10^9\)/L; \(p < 0.001\)), and albumin (23.8 vs. 32.9 g/L; \(p < 0.001\)).

Table 4 shows the correlation between renal function indicators, including eGFR, SCr, blood urea, and different laboratory parameters among the 250 COVID-19 patients’ cohort. There was a significant negative correlation between eGFR and CRP (\(r = -0.312\); \(p < 0.001\)), LDH (\(r = -0.247\); \(p < 0.001\)), blood urea (\(r = -0.524\); \(p < 0.001\)) and SCr (\(r = -0.484\); \(p < 0.001\)) as well as significant positive correlation with albumin (\(r = 0.271\); \(p < 0.001\)). There was a significant negative correlation between blood urea and hemoglobin (\(r = -0.256\); \(p < 0.001\)) and albumin (\(r = -0.270\); \(p < 0.001\)) but significant positive correlation with WCC (\(r = 0.171\); \(p = 0.007\)), CRP (\(r = 0.318\); \(p < 0.001\)), LDH (\(r = 0.280\); \(p < 0.001\)) and SCr (\(r = 0.807\); \(p < 0.001\)). There was a significant negative correlation between creatinine and hemoglobin (\(r = -0.165\); \(p = 0.009\)).

| Parameters, Pearson’s correlation coefficient | eGFR, mL/min | p-value | Urea, mmol/L | p-value | Creatinine, mmol/L | p-value |
|-----------------------------------------------|-------------|---------|--------------|---------|-------------------|---------|
| eGFR, mL/min                                  | 1           | -       | -0.524**     | < 0.001 | -0.484**          | < 0.001 |
| Neutrophil count, \(\times 10^9\)/L           | -0.098      | 0.123   | 0.128*       | 0.043   | 0.048             | 0.454   |
| Lymphocyte count, \(\times 10^9\)/L           | 0.083       | 0.191   | -0.040       | 0.534   | -0.030            | 0.640   |
| Hemoglobin, g/dL                              | 0.163*      | 0.010   | -0.256**     | < 0.001 | -0.165**          | 0.009   |
| White cell count, \(\times 10^9\)/L           | -0.089      | 0.163   | 0.171**      | 0.007   | 0.106             | 0.096   |
| Alanine transaminase, IU/L                    | 0.129*      | 0.042   | -0.015       | 0.814   | -0.031            | 0.621   |
| Aspartate aminotransferase, IU/L              | -0.009      | 0.891   | 0.064        | 0.311   | 0.037             | 0.561   |
| Alkaline phosphatase, IU/L                    | -0.117      | 0.066   | 0.091        | 0.149   | 0.041             | 0.518   |
| Platelets, \(\times 10^9\)/L                  | 0.094       | 0.139   | 0.046        | 0.473   | 0.036             | 0.567   |
| C-reactive protein, mg/dL                     | -0.312**    | < 0.001 | 0.318**      | < 0.001 | 0.170**           | 0.008   |
| Sodium, mmol/L                                | 0.105       | 0.099   | -0.082       | 0.198   | -0.113            | 0.075   |
| Lactated dehydrogenase, U/L                   | -0.247**    | < 0.001 | 0.280**      | < 0.001 | 0.150*            | 0.028   |
| Potassium, mmol/L                             | 0.005       | 0.936   | -0.002       | 0.976   | -0.006            | 0.920   |
| Bilirubin, \(\mu\)mol/L                      | -0.050      | 0.436   | 0.089        | 0.162   | -0.001            | 0.990   |
| Urea, mmol/L                                  | -0.524**    | < 0.001 | 1.000        | -       | 0.807**           | < 0.001 |
| Creatinine, \(\mu\)mol/L                     | -0.484**    | < 0.001 | 0.807**      | < 0.001 | 1.000             | -       |
| Albumin, g/L                                  | 0.271**     | < 0.001 | -0.270**     | < 0.001 | -0.166**          | 0.009   |

eGFR; estimated glomerular filtration rate.
Three cases (out of the 250) had missing serum creatinine levels and were not included in the eGFR calculations.
\(p\text{-value} < 0.05\); \(p\text{-value} < 0.01\).
DISCUSSION

To the best of our knowledge, this paper is the first to study the renal function and acute kidney injury among COVID-19 patients in the Middle East region. We determined the prevalence of kidney impairment in COVID-19 patients compared to the control group that represents patients visiting the hospital for other reasons during the study period. Our results showed that 45.4% of the COVID-19 patient cohort had reduced eGFR, with 13.8% of patients having moderate to severe kidney impairment.

These results are in line with a recent large prospective study that reported more than 40% of COVID-19 patients with evidence of renal involvement, including elevated blood urea and creatinine. Other researchers found that 33.9% of COVID-19 patients developed acute kidney injury. The high rate of renal impairment in our COVID-19 cohort could be attributed to the high prevalence of DM and hypertension in the region. Indeed, while only 1.6% of our COVID-19 patients had a previous history of chronic kidney diseases, 30.8% had a history of DM and 30.4% had a history of hypertension, in which both were considered major risk factors for the development of chronic kidney disease and reduced eGFR.

Our results showed that male patients were more vulnerable to more advanced impairment in the eGFR levels than female patients. This concurs with our previous observation that the male gender is associated with a more severe form of COVID-19 illness and worse outcome. In addition, another report had found that COVID-19 patients admitted to the hospital and had elevated SCr were predominantly males.

Acute renal impairment was reported in around 7% of patients diagnosed with SARS in 2003, with increased mortality rates of 90%. Similarly, recent publications have reported that acute kidney injury (AKI) was a common finding among COVID-19 patients, and its presence might determine the death risk of those patients. Moreover, reports showed high levels of SCr and blood urea nitrogen in around 15% of COVID-19 patients. Similarly, CT scans performed on most kidneys of COVID-19 patients showed evidence of reduced kidney density, which further highlights the acute renal injury.

Our results also showed a significant association between COVID-19 disease severity, admission to the ICU, and the degree of renal impairment. This finding is in line with reports showing critically ill COVID-19 patients having significantly higher AKI rates (42.9%) compared to other patients. Moreover, COVID-19 patients who develop AKI were found to have a more than five-fold increase in the risk of mortality compared to patients without evidence of AKI. AKI has also been found to be an independent risk factor for in-hospital mortality.

We found a significant correlation between eGFR levels and serum albumin. Reduced eGFR levels were associated with significantly lower serum albumin. This low albumin levels could be attributed to the proteinuria, usually associated with AKI and observed to be a common finding in patients with COVID-19.

A close association was also found between all the renal function indicators and CRP, which was recently proposed as a marker to predict the risk of COVID-19 aggravation. Another interesting finding is the close correlation between eGFR, serum creatinine, and blood urea nitrogen with derangement in multiple parameters, including hematological parameters and liver enzymes. This highlights the multiple organ involvement previously observed during SARS in 2003 and confirmed during the COVID-19 outbreak.

Although the exact mechanism that might explain the renal involvement in COVID-19 infection is still unclear, many mechanisms have been proposed. These include direct tubular injury due to the virus itself, which is supported by the finding that angiotensin-converting enzyme receptor 2 (ACE2), which is essential for the binding of SARS-CoV, was highly expressed in the kidney and renal tubular cells as well as the finding that viral RNA can be detected in the urine samples of COVID-19 patients. In addition to the dysregulation of the ACE2 system, and the thrombotic events, pro-inflammatory cytokine
storm found to be associated with COVID-19 infection is also proposed as a possible mechanism that might explain the AKI observed in patients with COVID-19 infection.  

CONCLUSION

Our study found a high prevalence of renal impairment in patients with COVID-19 infection. The results also demonstrated a significant correlation between renal function indicators and derangement in different laboratory markers, including hematological indices and liver enzymes. In addition, the severity of renal impairment was significantly associated with a more severe clinical course and subsequently increased the risk of ICU admission. These highlight the importance of evaluating the renal function and renal function indicators as predictive markers for COVID-19 progression. Hence, the study findings might help in early and effective intervention for high-risk COVID-19 patients, improving the disease outcomes and subsequently reducing COVID-19 associated morbidity and mortality.

Disclosure

The authors declared no conflicts of interest. No funding was received for this study.

Acknowledgements

We would like to thank all our patients for their patience. Also, we highly appreciate our colleagues and staff for their tremendous hard work during this crisis. In addition, we extend our gratitude to all staff at the Research Ethics Committee and the tremendous hard work during this crisis. In addition, we extend our gratitude to all staff at the Research Ethics Committee and the tremendous hard work during this crisis. 

REFERENCES

1. Zhu H, Wei L, Niu P. The novel coronavirus outbreak in Wuhan, China. Glob Health Res Policy 2020; 5:6.
2. Matoba Y, Abiko C, Ikeda T, Aoki Y, Suzuki Y, Yahagi K, et al. Detection of the human coronavirus 229E, HKU1, NL63, and OC43 between 2010 and 2013 in Yamagata, Japan. Jpn J Infect Dis 2015;68(2):138-141.
3. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical characteristics of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020 Feb;395(10223):497-506.
4. Petrosillo N, Viceconte G, Ergonul O, Ippolito G, Petersen NA, et al. Detection of the human coronavirus 229E, HKU1, NL63, and OC43 between 2010 and 2013 in Yamagata, Japan. Jpn J Infect Dis 2015;68(2):138-141.
5. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA 2020 Apr;323(13):1239-1242.
6. Khamis F, Al Rashidi B, Al-Zakwani I, Al Wahibi AH, Al Awaidy ST. Epidemiology of COVID-19 infection in Oman: analysis of the first 1304 cases. Oman Med J 2020 Jun;35(3):145.
7. Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. China medical treatment expert group for COVID-19. Comorbidity and its impact on 1590 patients with COVID-19 in China: a retrospective analysis. Eur Respir J 2020 May;55(5):2000547.
8. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. China medical treatment expert group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020 Apr;382(18):1708-1720.
9. Jin JM, Bai P, He W, Wu F, Liu XF, Han DM, et al. Gender differences in patients with COVID-19: focus on severity and mortality. Front Public Health 2020 Apr;8:152.
10. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhān, China: a descriptive study. Lancet 2020 Feb;395(10223):507-513.
11. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int 2020 May;97(5):829-838.
12. Tsang KW, Ho PL, Ooi GC, Yee WK, Wang T, Chan-Yeung M, et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003 May;348(20):1977-1985.
13. Argenziano MG, Bruce SL, Slater CL, Tiao JR, Baldwin MR, Barr RG, et al. Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series. BMJ 2020 May;369:m1969.
14. Hamoudi R, Saheb Sharif-Askari N, Saheb Sharif-Askari F, Abusnana S, Aljaibeji H, Taneera J, et al. Pre diabetes and diabetes prevalence and risk factors comparison between ethnic groups in the United Arab Emirates. Sci Rep 2019 Nov;9(1):17437.
15. Razzaq HA, Harbi A, Shelpai W, Qawas A. Prevalence and risk factors of cardiovascular disease in the United Arab Emirates. Hamdan Medical Journal 2018;11:105-111.
16. Duan JY, Duan GC, Wang CJ, Liu DW, Qiao YJ, Pan SK, et al. Prevalence and risk factors of chronic kidney disease and diabetic kidney disease in a central Chinese urban population: a cross-sectional survey. BMC Nephrol 2020 Apr;21(1):115.
17. Hachim IY, Hachim MY, Nacem KB, Hannawi H, Salmi IA, Hannawi S. Male Gender is a risk factor for sever form of COVID-19 illness and worse outcome in the Middle East. Research Square. 2020.
18. Chu KH, Tsang WK, Tang CS, Lam MF, Lai FM, To KF, et al. Acute renal impairment in coronavirus-associated severe acute respiratory syndrome. Kidney Int 2005 May;67(2):698-705.
19. Saheb Sharif-Askari N, Saheb Sharif-Askari F, Abusnana S, Aljaibeji H, Taneera J, et al. Pre diabetes and diabetes prevalence and risk factors comparison between ethnic groups in the United Arab Emirates. Sci Rep 2019 Nov;9(1):17437.
20. Naecker S, Yang CW, Hwang SJ, Liu BC, Chen JH, Jha V. The novel coronavirus 2019 epidemic and kidneys. Kidney Int 2020 May;97(5):824-828.
21. Zhang F, Liang Y. Potential risk of the kidney vulnerable to novel coronavirus 2019 infection. Am J Physiol Renal Physiol 2020 May;318(5):F1136-F1137.
22. Li Z, Wu M, Yao J, Guo J, Liao X, Song S, et al. Caution on kidney dysfunctions of 2019-nCoV patients. medRxiv 2020020820201212. 2020.
23. Gabarre P, Dumas G, Dupont T, Darmon M, Azoulay E, Zafrani L. Acute kidney injury in critically ill patients with COVID-19. Intensive Care Med 2020 Jul;46(7):1339-1348.
24. Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol 2020 May;109(5):531-538.
25. Battie D, Soler MJ, Sparks MA, Hiremath S, South AM, Welling PA, et al; COVID-19 and ACE2 in cardiovascular, lung, and kidney working group. Acute kidney injury in COVID-19: emerging evidence of a distinct pathophysiology. J Am Soc Nephrol 2020 Jul;31(7):1380-1383.
25. Khamis F, Al-Zakwani I, Al Naamani H, Al Lawati S, Pandak N, Omar MB, et al. Clinical characteristics and outcomes of the first 63 adult patients hospitalized with COVID-19: An experience from Oman. J Infect Public Health 2020 Jul;13(7):906-913.

26. Wang G, Wu C, Zhang Q, Wu F, Yu B, Lv J, et al. C-reactive protein level may predict the risk of COVID-19 aggravation. Open forum infect dis. 2020; 7: ofaa153.

27. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003 Nov;426(6965):450-454.